Pregled bibliografske jedinice broj: 1252193
Treatment and Outcomes of Acute Myocardial Infarction in Patients With Polymyalgia Rheumatica With and Without Giant Cell Arteritis
Treatment and Outcomes of Acute Myocardial Infarction in Patients With Polymyalgia Rheumatica With and Without Giant Cell Arteritis // The American Journal of Cardiology, 174 (2022), 12-19 doi:10.1016/j.amjcard.2022.03.034 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1252193 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Treatment and Outcomes of Acute Myocardial
Infarction in Patients With Polymyalgia Rheumatica
With and Without Giant Cell Arteritis
Autori
Sokhal, Balamrit S. ; Matetić, Andrija ; Bharadwaj, Aditya ; Helliwell, Toby ; Abhishek, Abhishek ; Mallen, Christian D. ; Mohamed, Mohamed O. ; Mamas, Mamas A.
Izvornik
The American Journal of Cardiology (0002-9149) 174
(2022);
12-19
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
CARDIOVASCULAR-DISEASE ; RISK ; GLUCOCORTICOIDS ; COMPLICATIONS ; MANAGEMENT ; TYPE-2 ; AGE
Sažetak
This study analyzed the characteristics, management, and outcomes of patients with poly- myalgia rheumatica (PMR) hospitalized with acute myocardial infarction (AMI), including sensitivity analysis for presence of giant cell arteritis (GCA). Using the National Inpatient Sample (January 2004 to September 2015) and International Classification of Diseases, Ninth Revision, all AMI hospitalizations were stratified into main groups: PMR and no-PMR ; and subsequently, PMR, PMR with GCA, and GCA and no-PMR. Outcomes were all- cause mortality, major adverse cardiovascular/cerebrovascular events (MACCEs), major bleeding, and ischemic stroke as well as coronary angiography (CA) and percutaneous coronary intervention (PCI). Multivariable logistic regression was used to determine adjusted odds ratios with 95% confidence interval (95% CI). A total of 7, 622, 043 AMI hospitalizations were identified, including 22, 597 patients with PMR (0.3%) and 5, 405 patients with GCA (0.1%). Patients with PMR had higher rates of mortality (5.8% vs 5.4%, p = 0.013), MACCEs (10.2% vs 9.2%, p<0.001), and stroke (4.6% vs 3.5%, p<0.001) and lower receipt of CA (48.9% vs 62.6%, p<0.001) and PCI (30.6% vs 41.0%, p<0.001) than the no-PMR group. After multivariable adjustment, patients with PMR had decreased odds of mortality (0.75, 95% CI 0.71 to 0.80), MACCEs (0.78, 95% CI 0.74 to 0.81), bleeding (0.79, 95% CI 0.73 to 0.86), and stroke (0.88, 95% CI 0.83 to 0.93) ; no difference in use of CA (1.01, 95% CI 0.98 to 1.04) and increased odds of PCI (1.07 95% CI 1.03 to 1.10) compared with the no-PMR group. Similar results were observed for patients with concomitant PMR and GCA, whereas patients with GCA only showed increased odds of bleeding (1.51 95% CI 1.32 to 1.72) and stroke (1.31 95% CI 1.16 to 1.47). In conclusion, patients with AMI with PMR have an increased incidence of crude adverse in-hospital outcomes than those without PMR ; however, these differences do not persist after adjusting for age and comorbidities.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE